Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Neuro-Oncology|October 10, 2022
Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymomaRui Fu, Gregory A Norris, Nicholas Willard, et al.
Iscience|September 11, 2023
Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymomaAndrea M Griesinger, Kent Riemondy, Nithyashri Eswaran, et al.
Neuro-Oncology|January 12, 2022
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium StudyTimothy A Ritzmann, Rebecca J Chapman, John-Paul Kilday, et al.
Cancers|January 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European RegistryBertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Cancers|March 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124Bertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Neuro-Oncology|May 29, 2023
Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter studyAndrew M Donson, Kelsey C Bertrand, Kent A Riemondy, et al.
Neuro-Oncology|March 14, 2023
Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA studyRebecca J Chapman, David R Ghasemi, Felipe Andreiuolo, et al.
Acta Neuropathologica|June 18, 2018
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomasKristian W Pajtler, Ji Wen, Martin Sill, et al.
Pageof 2